Tejara Capital Ltd holds 5.3% of Cardiol Therapeutics, representing 6,382,551 Class A common shares. The ownership is reported as passive, meaning the securities were acquired in the ordinary course and not to change or influence control of Cardiol Therapeutics.

Key Highlights

  • Tejara Capital Ltd is described as a Fund Manager authorised by the FCA in UK.
  • The reported fund, Trefoil Select Funds SPC-Stylus SP, is registered in Cayman.
  • Tejara Capital Ltd reports a 5.3% ownership position in Cardiol Therapeutics.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. Tejara Capital Ltd reports ownership of 5.3% of Cardiol Therapeutics, equal to 6,382,551 Class A common shares.

Passive Ownership Report Details

The amended Schedule 13G/A identifies Trefoil Select Funds SPC-Stylus SP as the fund connected with the position. Tejara Capital Limited is described as the fund manager, with the fund registered in Cayman and the manager based in the United Kingdom. The record also identifies the fund’s correspondence arrangements through Apex Funds Services Cayman Ltd in Grand Cayman. Tejara’s listed address is in London. It also includes an undertaking to provide requested information that otherwise would be disclosed in a Schedule 13D. Miyan Mansur Mannan signed the certification as DIRECTOR on September 23, 2026.